Skip to main content
placeholder image

A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2016

Citation


  • Markman, B., De Souza, P. L., Dees, E. C., Gangadhar, T. C., Cooper, A., Roohullah, A., . . . Wang, H. (2016). A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.. Journal of Clinical Oncology, 34(15_suppl), 2526. doi:10.1200/jco.2016.34.15_suppl.2526

Web Of Science Accession Number


Start Page


  • 2526

End Page


  • 2526

Volume


  • 34

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2016

Citation


  • Markman, B., De Souza, P. L., Dees, E. C., Gangadhar, T. C., Cooper, A., Roohullah, A., . . . Wang, H. (2016). A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.. Journal of Clinical Oncology, 34(15_suppl), 2526. doi:10.1200/jco.2016.34.15_suppl.2526

Web Of Science Accession Number


Start Page


  • 2526

End Page


  • 2526

Volume


  • 34

Issue


  • 15_suppl

Place Of Publication